Novo Nordisk Resolves US Wegovy, Ozempic Shortage

Novo Nordisk says that the US Food and Drug Administration (FDA) has determined the shortage of Wegovy and Ozempic is resolved in the United States. The agency says that supply of these prescription GLP-1 medicines now meets or exceeds both current and projected demand.

"We are pleased the FDA has declared that supply of the only real, FDA-approved semaglutide medicines is resolved, affirming that Novo Nordisk is meeting or exceeding current and projected nationwide demand," says Dave Moore, President, Novo Nordisk. 

To meet demand, Novo Nordisk has been operating its production facilities continuously and regularly shipping all doses of Wegovy and Ozempic to wholesalers. The company has invested US$6.5 billion in US manufacturing expansion this year as part of its efforts to stabilize supply.

"No one should have to compromise their health due to misinformation and reach for fake or illegitimate knockoff drugs that pose significant safety risks to patients," says Moore.

Novo Nordisk has also launched an AI-powered app, Find My Meds, designed to help individuals locate available doses of Wegovy at nearby retail pharmacies. The tool aims to assist patients in finding their prescribed medication if it is unavailable at their preferred pharmacy, ensuring continuity of care.

Google Trends data shows that in Mexico, searches for Ozempic have steadily increased since 2022, reaching their highest point in March 2023, reports UNAM. The past shortage in the United States also led to a shortage in Mexico, as people sought to acquire the medication there. Stabilization of supply in the United States may help normalize the situation in Mexico. 

Novo Nordisk is celebrating 20 years in Mexico. The country’s obesity and diabetes rates make it an attractive market for weightloss and diabetes management drugs. Mexico is a key market for Novo Nordisk, which has expanded its clinical trial operations in the country over time.